Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Bayzed Health and Meinian Onehealth Forge Strategic Partnership to Build Integrated Full-Cycle Health Management Ecosystem

Fineline Cube May 19, 2026
Company Deals

Ande Healthcare Files Hong Kong IPO Prospectus as Leading Chinese Medical Consumables Innovator

Fineline Cube May 19, 2026
Company Deals

Accro Bioscience Secures $50M Series C to Advance RIPK2 Inhibitor AC-101 into Phase IIb Ulcerative Colitis Trial

Fineline Cube May 19, 2026
Company Deals

Full-Life Technologies Secures $150M Financing to Advance Radiopharmaceutical Pipeline and Establish Independent Actinium-225 Production

Fineline Cube May 19, 2026
Company Deals

BMS Partners with Tigerlily Foundation to Address Racial Disparities in Breast Cancer Clinical Trial Access – Pharma Giant Commits to Improving Representation of Young Women of Color

Fineline Cube May 18, 2026
Policy / Regulatory

China Issues National Guidelines for Home Hospital Bed Services to Address Healthcare Access for Vulnerable Populations

Fineline Cube May 15, 2026
Company Drug

Merck’s Sacituzumab Tirumotecan Demonstrates First-Ever OS and PFS Benefit in Phase 3 Endometrial Cancer Trial

Fineline Cube May 19, 2026
Company Drug

GSK’s Arexvy RSV Vaccine Receives Expanded Japanese Approval for Adults 18-49 at Increased Risk

Fineline Cube May 19, 2026
Company Deals

AbbVie to Acquire Cerevel Therapeutics for $8.7 Billion, Strengthening Neuroscience Portfolio

Fineline Cube Dec 7, 2023

AbbVie (NYSE: ABBV) has announced its agreement to acquire Cerevel Therapeutics (NASDAQ: CERE) for approximately...

Company Drug

Shenzhen TargetRx’s TGRX-678 Set to Receive Breakthrough Therapy Designation for CML-AP

Fineline Cube Dec 7, 2023

Shenzhen TargetRx, Inc., a China-based developer of small-molecule kinase inhibitors, is poised to receive breakthrough...

Company Deals

Quinovare Partners with AIM Vaccine to Enhance Vaccine Accessibility in China

Fineline Cube Dec 7, 2023

Quinovare Medical Technology Co., Ltd., a China-based specialist in needle-free injectors, has announced a strategic...

Company Deals

Hisilicon Medical Technology Secures Nearly RMB 100 Million in Series A Funding

Fineline Cube Dec 7, 2023

Guangdong Hisilicon Medical Technology Co., Ltd., a China-based firm, has successfully raised nearly RMB 100...

Company Drug

Changchun BCHT Secures NMPA Approval for Freeze-Dried Human Rabies Vaccine Trials

Fineline Cube Dec 7, 2023

Changchun BCHT Biotechnology Co., Ltd. (SHA: 688276), based in China, has announced that it has...

Company Drug

Shanghai Pharmaceuticals Gains NMPA Approval for WST04 Clinical Trials in Oncology

Fineline Cube Dec 7, 2023

Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607), a leading pharmaceutical distribution company in China, has...

Company Drug

Jiangsu Hengrui Seeks NMPA Approval for Camrelizumab-Famitinib Combo in Cervical Cancer

Fineline Cube Dec 7, 2023

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276), based in China, has announced that its market...

Company Deals

Boehringer Ingelheim Partners with Ten63 Therapeutics to Discover Novel Drug Molecules

Fineline Cube Dec 7, 2023

Boehringer Ingelheim (BI), based in Germany, has announced a collaboration with U.S. drug discovery firm...

Company Drug

Antengene Secures NDA Approval for Xpovio in Macau for Advanced Multiple Myeloma

Fineline Cube Dec 7, 2023

Antengene Corp., Ltd. (HKG: 6996), a biopharmaceutical company based in China, has announced that it...

Company Deals

Innovent Biologics Expands Partnership with Synaffix for New ADC Development

Fineline Cube Dec 7, 2023

Innovent Biologics Inc. (HKG: 1801) has announced an expanded partnership with U.S.-based Synaffix B.V., a...

Company Deals

Taiwan Bio and TRACT Therapeutics Forge Partnership to Combat Organ Rejection

Fineline Cube Dec 7, 2023

Taiwan Bio Therapeutics Co., Ltd. has entered into a strategic partnership with U.S.-based TRACT Therapeutics,...

Company

Pfizer Allegedly Disbands Prevenar 13 Team in China Amid Industry Competition

Fineline Cube Dec 6, 2023

Unconfirmed online reports suggest that Pfizer (NYSE: PFE) has dismissed its entire 400-person team for...

Company Drug

Novartis’ Fabhalta Wins FDA Nod as First-in-Class Treatment for Paroxysmal Nocturnal Hemoglobinuria

Fineline Cube Dec 6, 2023

Swiss pharmaceutical giant Novartis (NYSE: NVS) has secured regulatory approval from the US Food and...

Company Deals

AbbVie Partners with BigHat Biosciences to Develop Next-Gen Antibodies for Oncology and Neuroscience

Fineline Cube Dec 6, 2023

AbbVie (NYSE: ABBV) has enlisted the expertise of BigHat Biosciences, a US-based company specializing in...

Company

J&J Forecasts 5-7% CAGR Through 2030, Driven by Innovative Medicine and Device Growth

Fineline Cube Dec 6, 2023

Johnson & Johnson (J&J; NYSE: JNJ) has presented an update on its business strategy, pipeline,...

Company Drug

China Medical System’s Methotrexate Injection Receives NMPA Review for Rheumatoid Arthritis Indication

Fineline Cube Dec 6, 2023

China Medical System Holdings (CMS; HKG: 0867) has announced that the National Medical Products Administration...

Company Medical Device

Sinocare Inc’s Blood Glucose Monitoring System Earns US FDA Approval

Fineline Cube Dec 6, 2023

Sinocare Inc (SHE: 300298), a Chinese medical device company, has announced that it has received...

Company Drug

Huadong Medicine Gets NMPA Green Light for Sirolimus Real-World Study in Pediatric Epilepsy

Fineline Cube Dec 6, 2023

Huadong Medicine Co., Ltd (SHE: 000963), a Chinese pharmaceutical company, has received approval from the...

Company Drug

Sino Biopharmaceutical Initiates Phase I Trial for Hepatitis B siRNA Drug TQA3038

Fineline Cube Dec 6, 2023

Sino Biopharmaceutical Ltd (HKG: 1177), a leading biopharmaceutical company based in China, has announced the...

Company Drug

Jingxin Pharmaceutical’s Didaxini Gains NMPA Approval as Category 1 Drug

Fineline Cube Dec 6, 2023

Jingxin Pharmaceutical Co., Ltd (SHE: 002020), a Chinese pharmaceutical company, has announced that it has...

Posts pagination

1 … 434 435 436 … 667

Recent updates

  • Merck’s Sacituzumab Tirumotecan Demonstrates First-Ever OS and PFS Benefit in Phase 3 Endometrial Cancer Trial
  • Bayzed Health and Meinian Onehealth Forge Strategic Partnership to Build Integrated Full-Cycle Health Management Ecosystem
  • Ande Healthcare Files Hong Kong IPO Prospectus as Leading Chinese Medical Consumables Innovator
  • GSK’s Arexvy RSV Vaccine Receives Expanded Japanese Approval for Adults 18-49 at Increased Risk
  • Taiji Industry Secures NMPA Clinical Trial Approval for DSC158A, Next-Generation Influenza RNA Polymerase Inhibitor
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Merck’s Sacituzumab Tirumotecan Demonstrates First-Ever OS and PFS Benefit in Phase 3 Endometrial Cancer Trial

Company Deals

Bayzed Health and Meinian Onehealth Forge Strategic Partnership to Build Integrated Full-Cycle Health Management Ecosystem

Company Deals

Ande Healthcare Files Hong Kong IPO Prospectus as Leading Chinese Medical Consumables Innovator

Company Drug

GSK’s Arexvy RSV Vaccine Receives Expanded Japanese Approval for Adults 18-49 at Increased Risk

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.